Detalles de la búsqueda
1.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621400
2.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int
; 133 Suppl 3: 57-67, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986556
3.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990608
4.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36261050
5.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581798
6.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31157964
7.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028967
8.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
BJU Int
; 124 Suppl 1: 5-13, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31638341
9.
The impact of coronavirus disease 2019 on genitourinary and prostate cancer care and clinical trials: A qualitative exploration of the Australian and New Zealand experience.
Asia Pac J Clin Oncol
; 19(3): 337-346, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36281656
10.
Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.
JCO Oncol Pract
; 19(11): 973-980, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37327464
11.
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Eur Urol Oncol
; 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37806844
12.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34928708
13.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34030924
14.
The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group--a new co-operative cancer trials group in genitourinary oncology.
BJU Int
; 115(6): 856-8, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25195815
15.
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.
J Clin Oncol
; 29(15): 2077-84, 2011 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-21483008
Resultados
1 -
15
de 15
1
Próxima >
>>